GABRIELA GONZALEZ: Open Payments
NPI 1457815797 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,977 in 88 payments from 16 companies in 2025. Trend: 2023 $494 · 2024 $2,246 · 2025 $1,977
Food & beverage: $1,977
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $566 |
| Madrigal Pharmaceuticals | 11 | $350 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 13 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $208 |
| Phathom Pharmaceuticals, Inc. | 4 | $164 |
| GENZYME CORPORATION | 3 | $109 |
| Gilead Sciences, Inc. | 4 | $89 |
| Janssen Biotech, Inc. | 2 | $48 |
| PFIZER INC. | 3 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $36 |
Products named: REZDIFFRA, RINVOQ, XIFAXAN, MAVYRET, VOQUEZNA, LINZESS, DUPIXENT, ENTYVIO.
Industry payments across TX — which companies pay providers there.
